Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants
News

Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants

Relonchem receives marketing authorization for Moxonidine tablets

  • By IPP Bureau | September 24, 2025

Relonchem receives marketing authorization for Moxonidine tablets

Marksans Pharma Limited’s wholly owned subsidiary Relonchem Limited in UK has received marketing authorization for Moxonidine 200 microgram Tablets and Moxonidine 400 microgram Tablets from UK MHRA.

Patel Chem Specialities inks agreement with J&H Pharma Consultants

Patel Chem Specialities has executed an independent turnkey project service agreement with J & H Pharma Consultants for the Indrad plan. The total consideration of Rs 45 crore.  J & H Pharma Consultants is responsible for designing, engineering, procuring, constructing, and testing the project, and then handing it over to the Patel Chem Specialities in a fully operational condition.

Other Related stories

Startup

Digitization

India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
India is becoming centre of innovation and global execution: Sanjay Vyas, President and MD, Parexel India
Sanjay Vyas President and Managing Director, Parexel India And Global SBU Head- Safety services & Logistics, Parexel International